

Annual Review of Xopenex® (levalbuterol) Nebulizer Solution and HFA

Oklahoma Health Care Authority, December 2008

Prior Authorization Criteria

The nebulizer solution and HFA will require prior authorization with a 3 day* emergency supply allowance. If long-term authorization is needed, the following criteria must be met:

1. In the prior authorization request, the prescriber should document why the member is unable to use racemic albuterol. For those members with asthma, members should also be utilizing inhaled corticosteroid (ICS) therapy for long-term control per NAEPP guidelines.
2. Dose of levalbuterol requested cannot be less than the racemic equivalent documented on the prior authorization request.

Quantity Limits

- For Nebulization Solution – 288units/30 day supply
- For HFA inhaler – 30units/30 day supply

**Due to supplemental rebate participation, there is currently a free floating 90 days of therapy per 365 days on the solution and open access on the HFA.*

Utilization Trends

Fiscal Year	Members	Claims	Cost	Cost/Claim	Perdiem	Units	Days
2007	13,030	24,397	\$2,664,694.27	\$109.22	\$5.36	2,612,306	497,395
2008	12,888	25,868	\$3,278,557.12	\$126.74	\$6.39	2,826,652	512,776
Percent Change	-1.10%	6.00%	23.00%	16.00%	19.20%	8.20%	3.10%
Change	-142	1,471	\$613,862.85	\$17.52	\$1.03	214,346	15,381

Utilization Details FY 2008

Brand Name	Claims	Members	Units	Days	Perdiem	% Cost	Claims/Member
XOPENEX NEB 0.63MG	10,250	5,728	1,475,848	185,512	\$8.52	48.21%	1.79
XOPENEX HFA AER	6,645	3,530	116,173	169,581	\$2.21	11.43%	1.88
XOPENEX NEB 1.25/3ML	4,624	2,375	693,236	86,877	\$8.46	22.41%	1.95
XOPENEX NEB 0.31MG	4,336	2,618	540,779	70,583	\$8.31	17.89%	1.66
XOPENEX NEB 1.25/0.5	13	13	616	223	\$8.87	0.06%	1
Totals	25,868	12,888*	2,826,652	512,776	\$6.39	100%	2.01

*Unduplicated members.

Demographics for Xopenex™

FY 08	Male	Female
00-09	5,538	3,949
10-19	1,157	955
20-34	60	305
35-49	66	286
50-64	146	343
65-79	19	37
80-94	4	2

Demographics for Solution

FY 08	Male	Female
00-09	4,942	3,419
10-19	614	469
20-34	33	133
35-49	41	149
50-64	81	210
65-79	14	26
80-94	3	1

Demographics for Inhaler

FY 08	Male	Female
00-09	926	695
10-19	664	581
20-34	28	191
35-49	26	155
50-64	70	163
65-79	7	12
80-94	1	1

Top Ten Prescriber Specialty of Xopenex™

Specialty	Claims	Cost
General Pediatrician	10,284	\$1,440,068.39
Family Practitioner	6,556	\$747,122.48
Nurse Practitioner	1,784	\$210,362.45
Physician Assistant	1,629	\$184,713.45
General Practitioner	1,429	\$191,886.76
Unknown	1,066	\$120,889.92
Internist	884	\$120,641.65
DDSD-NFM	528	\$70,475.69
Allergist	314	\$34,305.26
ER Practitioner	309	\$29,589.21
General Surgeon	172	\$20,439.55

Prior Authorization of Xopenex™

Approved	402
Denied	371
Incomplete	298
Total	1,071

Conclusions

The College of Pharmacy recommends no changes to this category at this time.